A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Citations Over TimeTop 10% of 2020 papers

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.

Related Papers

• → Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma(2021)54 cited
• → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited
• → Heterogeneity in the Properties of 7 S and 19 S Rabbit-Neutralizing Antibodies to Herpes Simplex Virus(1968)101 cited
• → Fachinformationen zu SARS-CoV-2/COVID-19(2020)